USP15 stabilized FIS1, suppressed oxidative phosphorylation, and increased radiosensitivity; metformin restored radiation response in USP15-low bladder cancer models.
Leave-one-cancer-type-out genomic scores remained associated with progression in five of eight cancers, with the largest performance gain in cervical cancer.
AI-assisted planning cut average planning time from about two hours to 30 minutes, but three of 12 plans required manual hotspot correction.
The programme prepared 256 children for radiotherapy and was associated with avoidance of daily general anaesthesia in five selected cases.
Brief virtual-reality training increased self-reported procedural confidence, but knowledge, technical skill, retention, and clinical performance were not tested.
No grade 3 toxicity occurred after five-fraction MR-guided salvage radiotherapy, while urinary and bowel quality-of-life scores remained stable.
Iodine-125 seed implantation produced 90% three-month disease control, but median local progression-free survival was nine months.
Pretreatment lymphocyte-to-monocyte ratio was independently associated with cervical tumour shrinkage, but its standalone discrimination was poor.
Systemic tetrathiomolybdate reduced collagen deposition and preserved saliva secretion after irradiation of mouse submandibular glands.
Convection-enhanced actinium-225 markedly reduced modelled clonogenic survival, but effective coverage extended only about 1.4 cm from each catheter.
Gold nanoparticles increased proton-induced clonogenic killing from 4 Gy onward, with similar sensitization using 20- and 50-nm particles.
Twenty-five selected patients had 96% crude local control and no grade 3 toxicity after 26 Gy in five fractions.
Adding CTV radiomics increased internal AUROC from 0.507 to 0.754 for predicting poor response to rectal chemoradiotherapy.
Triple oHSV, radiotherapy and IGF1R blockade suppressed YAP1, produced tumour regressions and prolonged survival in glioblastoma and breast cancer models.
Radiation reached 60 Gy in 15 fractions with adjuvant atezolizumab, while concurrent dosing was followed by HSV-1 reactivation in three of five patients.